

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **May 2019**

Commission File Number: **001-38480**

**IMV Inc.**

*(Name of registrant)*

**130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**IMV Inc.**

Date: May 10, 2019

By: /s/ Pierre Labbé

Name: Pierre Labbé

Title: Chief Financial Officer

---

**Form 6-K Exhibit Index**

<b>Exhibit Number</b>	<b>Document Description</b>
<a href="#">99.1</a>	<a href="#">News Release dated May 10, 2019 IMV Inc. Announces Q1 2019 Financial Results and Clinical Program Advances.</a>

---



### IMV Inc. Announces Q1 2019 Financial Results and Clinical Program Advances

**Dartmouth, Nova Scotia; May 9, 2019** – IMV Inc. (TSX: IMV; TSX: NASDAQ), a clinical stage immunotherapy company, today released its financial and operational results for the first quarter ended March 31, 2019.

“The DPX-Survivac program continues to be a major value-driver for IMV, with its unique mechanism of action providing significant clinical differentiation and, potentially, a much-needed innovation for hard-to-treat cancers,” said [Frederic Ors, IMV's Chief Executive Officer](#). “Highlights of our overall progress this quarter include:

- Reported [promising initial data](#) from the phase 2 cohort of the DeCidE1 clinical study, which underscores the potential of DPX-Survivac as a monotherapy;
- Awarded a grant with le Centre de Recherche du CHU de Québec-Université Laval [to develop a first-in-class dual target T cell therapy](#) in bladder cancer; and
- [Completed a C\\$29.46 million financing](#) with Wells Fargo acting as lead underwriter that provided the Company with increased financial flexibility.”

#### **DPX-Survivac Clinical Program Updates:**

##### **Phase 2 Cohort of the DeCidE1 Clinical Study in Ovarian Cancer**

IMV provided a clinical update in March indicating that six patients receiving DPX-Survivac monotherapy with intermittent low-dose cyclophosphamide (mCPA) had reached the first CT scan assessment. Key related findings were as follows:

- 83% of the participants (5 of 6) showed stable disease (SD), including two tumor regressions; and
- 80% (4 of 5) of those with stable disease were subjects with a lower baseline tumor burden (BTB) of less than 5 centimeters, which also included the two tumor regressions.

In earlier stages of this trial, durable clinical responses occurred after 140 days, and at the date of this latest update, they had lasted for 20 months or more. The amended phase 2 cohort of the DeCidE1 trial focuses on patients with low BTB (less than 5 centimeters). The Corporation is targeting enrollment of at least 16 additional patients at sites in the U.S. and Canada.

IMV will present additional data on DeCidE1 at the 2019 American Society of Clinical Oncology (ASCO) annual meeting.

##### **Phase 2 Study in Combination with KEYTRUDA® in Relapsed/Refractory DLBCL (SPiReL)**

As of April 5, 2019, investigators had enrolled ten patients in four different clinical sites in Canada. Additional patients are being screened and IMV expects to report updated clinical data

at the bi-annual [International Conference on Malignant Lymphoma](#), which will be held in Lugano Switzerland in June 2019.

### **Phase 2 Basket Trial in Combination with KEYTRUDA® in Multiple Solid Tumors**

Screening and enrollment of patients is ongoing at multiple clinical sites across the U.S. and Canada for 5 cohorts of patients with bladder, liver (hepatocellular carcinoma), ovarian, or non-small cell lung (NSCLC) cancers, as well as tumors shown to be positive for the microsatellite instability high (MSI-H) biomarker.

The first patients have been treated in the ovarian, NSCLC and MSI-H cohorts and IMV expects to report preliminary clinical results on several of the solid tumor indications before the end of 2019.

### **The Corporation expects to reach the following milestones between now and the first half of 2020:**

<b>Milestones</b>	<b>Key dates</b>
Phase 2 monotherapy clinical results in Ovarian – ASCO	June 2019
Phase 2 clinical results with Merck Keytruda in DLBCL – ICML	June 2019
Preliminary clinical results Basket trial in 5 indications	H2 2019
Topline monotherapy clinical results in Ovarian	H2 2019
Top line clinical results for Basket trial	H1 2020

“We are pleased at the steady progress we’ve made this far in 2019, and look forward to leveraging our technology to improve immunotherapy treatment options, particularly in underserved cancers,” continued Mr. Ors. “We are grateful for the continued support of our shareholders and partners and look forward to a very productive remainder of 2019.”

### **Q1 2019 Operational Highlights**

**Completion of an underwritten public offering:** IMV completed, in early March 2019 an underwritten public offering of 5,404,855 common shares at a price to the public of C\$5.45 per common share, for aggregate gross of approximately C\$29.46 million, before deducting the underwriting commissions and estimated Offering expenses. Wells Fargo Securities and Raymond James acted as joint book-running managers for the Offering. B. Riley FBR acted as co-manager.

The Corporation intends to use the net proceeds of the Offering to accelerate the development of DPX-Survivac in combination with Keytruda as part of the basket trial in select advanced or recurrent solid tumors in bladder, liver (hepatocellular carcinoma), ovarian or non-small-cell lung cancers, as well as tumors shown to be positive for the microsatellite instability high biomarker and for general corporate purposes.

**Grant awarded by CQDM to IMV to develop first-in-class dual target T cell therapy:** In March, a grant was awarded by CQDM to develop a first-in-class dual target T Cell therapy in bladder cancer based on IMV’s DPX technology to IMV and Centre de Recherche du CHU de Québec-Université Laval.

---

The work will target immunogenic peptides from the MAGE protein family member A9 (MAGE-A9) as identified by a team from Centre de Recherche du CHU de Québec-Université Laval. This protein is frequently expressed in various human cancers including bladder, lung, and kidney. These peptides will be combined with selected immunogenic peptides from the survivin protein composing the DPX-Survivac T cell drug candidate.

### **Overview of Q1 2019 Financial Results**

The net loss and comprehensive loss of 5,943,000 (\$0.13 per share) for the three-month period ended March 31, 2019, was \$2,876,000 higher than the net loss and comprehensive loss for three-month period ended March 31, 2018. This relates mainly to a \$2,131,000 increase in research and development (R&D) expenses, a \$670,000 increase in general and administrative expenses and a \$71,000 increase in government assistance in the three-month period ended March 31, 2019.

At March 31, 2019, the Corporation had cash and cash equivalents of \$34,207,000 and working capital of \$33,893,000, compared with \$14,895,000 and \$12,247,000, respectively at December 31, 2018. For the three-month period ended March 31, 2019, IMV's cash burn rate (defined as net loss for adjusted for non-cash transactions including amortization, depreciation, accretion of long-term debt and stock-based compensation) was approximately \$5.2 million. Based on the current business plan, the Corporation forecasts the quarterly cash burn rate to be between \$5 million and \$6 million for 2019.

As of May 9, 2019, the number of issued and outstanding common shares was 50,597,306. A total of 2,030,471 stock options, warrants, and deferred share units were outstanding on May 9, 2019.

The Corporation's unaudited interim condensed consolidated results of operations, financial condition and cash flows for the three months ended March 31, 2019 and the related management's discussion and analysis (MD&A) are available on SEDAR at [www.sedar.com](http://www.sedar.com).

### **About IMV**

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company's proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells *in vivo*, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV's lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Connect at [www.imv-inc.com](http://www.imv-inc.com)

### **IMV Forward-Looking Statements**

*This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ*

---

*materially from those set forth in this press release due to risks affecting the Corporation, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties and those risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion of clinical trials, the receipt of all regulatory approvals and other risks detailed from time to time in our ongoing quarterly filings and annual information form. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV's continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at [www.sedar.com](http://www.sedar.com) and on EDGAR at [www.sec.gov/edgar](http://www.sec.gov/edgar).*

###

**Contacts for IMV:**

**INVESTOR RELATIONS:**

**Marc Jasmin, Senior Director, Investor Relations and Communications**

O: (902) 492-1819 ext : 1042

M: (514) 917-9481 E: [mjasmin@imv-inc.com](mailto:mjasmin@imv-inc.com)

**MEDIA:**

**Andrea Cohen, Sam Brown Inc.**

O: (917) 209-7163 E: [andreacohen@sambrown.com](mailto:andreacohen@sambrown.com)

---

IMV INC.

Unaudited Interim Condensed Consolidated Statements of Loss and Comprehensive Loss

(In thousands of Canadian dollars, except shares and per share amounts)

	Three-month ended	
	2019	March 31
	\$	2018
	\$	\$
<b>Revenue</b>		
Subcontract revenue	8	27
Interest Income	74	69
Total revenue	82	96
<b>Expenses</b>		
Research and development	4,013	1,882
General and administrative	1,960	1,290
Government assistance	(346)	(275)
Accreted interest	398	266
Total operating expenses	6,025	3,163
<b>Net loss and comprehensive loss</b>	<b>(5,943)</b>	<b>(3,037)</b>
<b>Basic and diluted loss per share</b>	<b>(0.13)</b>	<b>(0.07)</b>
Weighted-average shares outstanding	46,712,436	41,594,865

IMV INC.  
 Unaudited Interim Condensed Consolidated Statements of Financial Position  
 (Expressed in thousands of Canadian dollars except for per share amounts)

	March 31, 2019	December 31, 2018
<b>Assets</b>		
Current assets		
Cash and cash equivalents	\$ 34,207	\$ 14,895
Accounts receivable	878	1,337
Prepaid expenses	2,974	2,699
Investment tax credits receivable	1,456	1,111
Total current assets	39,515	20,042
Property and equipment	2,880	2,883
Total assets	\$ 42,395	\$ 22,925
<b>Liabilities and Equity</b>		
Current liabilities		
Accounts payable and accrued liabilities	\$ 5,383	\$ 7,575
Amounts due to directors	63	49
Current portion of long-term debt	84	81
Current portion of lease obligations	92	90
Total current liabilities	5,622	7,795
Lease obligation	1,285	1,308
Deferred share units	1,232	1,436
Long-term debt	8,444	8,069
Total liabilities	16,583	18,608
Equity	25,812	4,317
Total liabilities and equity	\$ 42,395	\$ 22,925